4.5 Article

Implementation Experience With Meningococcal Serogroup B Vaccines in the United States Impact of a Nonroutine Recommendation

Journal

PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 40, Issue 3, Pages 269-275

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0000000000003033

Keywords

Category B recommendation; meningococcal disease; serogroup B; shared clinical decision-making; vaccines

Funding

  1. Pfizer Inc.

Ask authors/readers for more resources

Studies show that healthcare providers in the US have poor understanding of ACIP's MenB vaccination recommendation, leading to potential misinterpretation. Parental awareness of MenB vaccines is low, with racial and socioeconomic disparities affecting vaccine coverage.
Background: Meningococcal serogroup B (MenB) is the leading cause of invasive meningococcal disease among US adolescents and young adults, accounting for 62% of cases in 16-23-year-olds in 2018. Since 2015, the Advisory Committee on Immunization Practices (ACIP) has recommended vaccination of healthy adolescents against MenB based on shared clinical decision-making (previously called Category B or individual clinical decision-making). However, MenB vaccine coverage and series completion rates remain low. Herein we examine implementation experience of adolescent MenB vaccination in the United States under this nonroutine ACIP recommendation. Methods: PubMed was searched for English-language articles published after 2015 examining MenB vaccination implementation in the United States. Studies reporting MenB vaccination awareness, coverage, knowledge of recommendations and implementation barriers or access disparities were included. Results: Identified studies provided evidence that ACIP's MenB vaccination recommendation is poorly understood and prone to misinterpretation by US healthcare providers. Parental awareness of MenB vaccines is low, and racial and socioeconomic disparities exist regarding vaccine receipt. Parents rely on providers to learn about MenB disease risk and benefits of vaccination, with provider recommendations carrying substantial weight in vaccination decisions. Conclusions: Five years of evidence regarding the MenB vaccination implementation experience suggest that the nonstandard recommendation for MenB vaccines is partly responsible for low vaccine coverage. Further, inconsistent implementation of ACIP recommendations could be limiting access to MenB vaccines. Providers need additional support and guidance to implement the shared clinical decision-making recommendation, in turn ensuring equitable access for vaccine-eligible adolescents to enable comprehensive protection against meningococcal disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available